Johan Askling, MD/PhD, Associate Professor

Research Area

Much of the work in my research group focuses on chronic inflammatory diseases, mainly Rheumatoid Arthritis (RA).

About 0.7% of the adult population has RA; one in thirty individuals in the general population will receive a diagnosis of RA during his/her lifetime. The etiology is unknown but seems to include genetic susceptibility and environmental triggers, and to be markedly different between different subsets of patients with RA, suggesting that the clinical concept of "RA" harbours not one disease but several diseases, each with its distinct etiology.

Apart from RA, other chronic inflammatory diseases of interest include inflammatory bowel disease, ankylosing spondylitis and other spondyloarthropaties, and Wegeners granulomatosis. All these diseases are characterized by highly variable disease courses and response to treatments, and by the presence or gradual development of co-morbid conditions that may account for the major burden of disease or premature mortality in the long run. In RA, for instance, there is a markedly increased risk of cardiovascular disease.

Another common feature for many chronic inflammatory diseases is the recent possibility to use biological therapies (typically antibodies directed against key pathways in the immune system). Over the last decade, nine different biological drugs have been introduced against RA. These therapies, intended for chronic use as they do not cure but suppress disease activity, may be effective but are costly and have incompletely understood safety profiles.

The overarching aims of my research are therefore to study the descriptive epidemiology, etiology, co-morbidity, drug safety, and outcome of chronic inflammatory diseases. To do this, we use clinical epidemiological methods based on linkages of clinical and other registers of patients with these diseases, their treatments, diseases, and outcome. In particular, we use the clinical quality of care registers in Rheumatology.

My research group constitutes the clinical epidemiological node in a research network also including genetics and genetic epidemiology, immunology, clinical Rheumatology and other research groups at Karolinska Institutet, at other Swedish universities, and internationally.

Main Grant Support

• Swedish Foundation for Strategic Research
• Swedish Cancer Society
• Karolinska Institutet / Stockholm County Counil (ALF, strategic grants)
• Swedish Research Council
• Public-private research consortium COMBINE

Five selected publications from 2010-2011

1. Raaschou P, Simard JF, Neovius M, Askling J for the Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis?: A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011 Jul;63(7):1812-22.

2. Neovius M, Simard JF, Klareskog L, Askling J for the ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis. 2011 Aug;70(8):1407-1414.

3. Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapaa-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology 2011; 50:204-213.

4. Soderlund S, Granath F, Brostrom O, Karlen P, Lofberg R, Ekbom A, Askling J. Inflammatory Bowel Disease Confers a Lower Risk of Colorectal Cancer to Females Than to Males. Gastroenterology 2010; 138:1697-U1696.

5. Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do Rheumatoid Arthritis and Lymphoma Share Risk Factors? A Comparison of Lymphoma and Cancer Risks Before and After Diagnosis of Rheumatoid Arthritis. Arthritis and Rheumatism 2010; 62:1252-1258.

Other

• Clinically active as board certified Rheumatologist at the Department of Rheumatology, Karolinska University Hospital

Full List of Publications

2011

Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J for the ARTIS Study Group. Treatment with tumour necrosis factor-inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2011 Aug 26 [Epub ahead of print]

Raaschou P, Simard JF, Neovius M, Askling J for the Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis?: A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011 Jul;63(7):1812-22.

Neovius M, Simard JF, Klareskog L, Askling J for the ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis. 2011 Aug;70(8):1407-1414.

Neovius M, Simard JF, Askling J for the ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis. 2011 Jun;70(6):1010-5.

Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):119-30.

Neovius M, Simard JF, Askling J for the ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011 Apr;70(4):624-9.

Neovius M, Simard J, Sundström A, Jacobsson L, Geborek P, Saxne T, Feltelius N, Klareskog L, Askling J for the ARTIS Study Group. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis. 2011 Mar;70(3):516-9

Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L for the ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol. 2011 Jan;40(1):8-15.

Askling J, Dixon W. Influence of biological agents on cardiovascular disease in rheumatoid arthritis. Ann Rheum Dis. 2011 Apr;70(4):561-2.

Saevarsdottir S, Wedrén S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, Askling J, Alfredsson L, Klareskog L. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011 Jan;63(1):26-36.

Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011 Jan;50(1):204-13.

Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, Zink A. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology (Oxford). 2011 Jan;50(1):146-51.

2010

Askling, J. (2010). "The risk of malignancies in RA patients treated with biologics." Zeitschrift Fur Rheumatologie 69(9): 774-+.

Bahmanyar, S., A. Ekbom, et al. (2010). "Cystic fibrosis gene mutations and gastrointestinal diseases." Journal of Cystic Fibrosis 9(4): 288-291.

Carlens, C., M. P. Hergens, et al. (2010). "Smoking, Use of Moist Snuff, and Risk of Chronic Inflammatory Diseases." American Journal of Respiratory and Critical Care Medicine 181(11): 1217-1222.

Cui, J., S. Saevarsdottir, et al. (2010). "Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy." Arthritis Rheum 62(7): 1849-1861.

Cui, J., S. Saevarsdottir, et al. (2010). "Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to Anti-Tumor Necrosis Factor alpha Therapy." Arthritis and Rheumatism 62(7): 1849-1861.

Curtis, J. R., A. Jain, et al. (2010). "A Comparison of Patient Characteristics and Outcomes in Selected European and US Rheumatoid Arthritis Registries." Seminars in Arthritis and Rheumatism 40(1): 2-14.

Dixon, W. G., L. Carmona, et al. (2010). "EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology." Annals of the Rheumatic Diseases 69(9): 1596-1602.

Hellgren, K., A. Iliadou, et al. (2010). "Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study." Annals of the Rheumatic Diseases 69(4): 654-659.

Hellgren, K., K. E. Smedby, et al. (2010). "Do Rheumatoid Arthritis and Lymphoma Share Risk Factors? A Comparison of Lymphoma and Cancer Risks Before and After Diagnosis of Rheumatoid Arthritis." Arthritis and Rheumatism 62(5): 1252-1258.

Holmqvist, M. and J. Askling (2010). "Ischemic heart disease and rheumatoid arthritis: comment on the article by Holmqvist et al Reply." Arthritis and Rheumatism 62(8): 2561-2561.

Holmqvist, M. E., S. Wedren, et al. (2010). "Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006." J Intern Med 268(6): 578-585.

Holmqvist, M. E., S. Wedren, et al. (2010). "Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006." Journal of Internal Medicine 268(6): 578-585.

Knight, A., S. Sandin, et al. (2010). "Increased Risk of Autoimmune Disease in Families with Wegener's Granulomatosis." Journal of Rheumatology 37(12): 2553-2558.

Knight, A., S. Sandin, et al. (2010). "Occupational risk factors for Wegener's granulomatosis: a case-control study." Annals of the Rheumatic Diseases 69(4): 737-740.

Norgaard, M., H. Larsson, et al. (2010). "Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study." Journal of Internal Medicine 268(4): 329-337.

Simard JF, Neovius M, Hagelberg S, Askling J.

Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010 Dec;62(12):3776-82.

Simon, T. A., J. Askling, et al. (2010). "Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment." Arthritis Res Ther 12(2): R67.

Simon, T. A., J. Askling, et al. (2010). "Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment." Arthritis Research & Therapy 12(2).

Soderberg, C., P. Stal, et al. (2010). "Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up." Hepatology 51(2): 595-602.

Soderlund, S., F. Granath, et al. (2010). "Inflammatory Bowel Disease Confers a Lower Risk of Colorectal Cancer to Females Than to Males." Gastroenterology 138(5): 1697-U1696.

Soderlund, S., B. Tribukait, et al. (2010). "Colitis-associated DNA aneuploidy and dysplasia in Crohn's disease and risk of colorectal cancer." Inflamm Bowel Dis.

2009

Askling, J., E. Baecklund, et al. (2009). "Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register." Annals of the Rheumatic Diseases 68(5): 648-653.

Askling, J., R. F. van Vollenhoven, et al. (2009). "Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?" Arthritis and Rheumatism 60(11): 3180-3189.

Carlens, C., L. Jacobsson, et al. (2009). "Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis." Annals of the Rheumatic Diseases 68(7): 1159-1164.

Elmberg, M., R. Hultcrantz, et al. (2009). "Increased Mortality Risk in Patients With Phenotypic Hereditary Hemochromatosis But Not in Their First-Degree Relatives." Gastroenterology 137(4): 1301-1309.

Holmqvist, M. E., S. Wedren, et al. (2009). "No Increased Occurrence of Ischemic Heart Disease Prior to the Onset of Rheumatoid Arthritis Results From Two Swedish Population-Based Rheumatoid Arthritis Cohorts." Arthritis and Rheumatism 60(10): 2861-2869.

Johannesson, M., J. Askling, et al. (2009). "Cancer risk among patients with cystic fibrosis and their first-degree relatives." International Journal of Cancer 125(12): 2953-2956.

Liao, K. P., M. Gunnarsson, et al. (2009). "Specific Association of Type 1 Diabetes Mellitus With Anti-Cyclic Citrullinated Peptide-Positive Rheumatoid Arthritis." Arthritis and Rheumatism 60(3): 653-660.

Nielsen, T. R., K. Rostgaard, et al. (2009). "Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis." Multiple Sclerosis 15(4): 431-436.

Simon, T. A., A. L. Smitten, et al. (2009). "Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment." Annals of the Rheumatic Diseases 68(12): 1819-1826.

Soderlund, S., L. Brandt, et al. (2009). "Decreasing Time-Trends of Colorectal Cancer in a Large Cohort of Patients With Inflammatory Bowel Disease." Gastroenterology 136(5): 1561-1567.

Soderlund, S., L. Brandt, et al. (2009). "Is Ulcerative Colitis Proctitis Associated With an Increased Risk of Colorectal Cancer? Reply." Gastroenterology 137(5): 1858-1858.

Zink, A., J. Askling, et al. (2009). "European biologicals registers: methodology, selected results and perspectives." Annals of the Rheumatic Diseases 68(8): 1240-1246.

2008

Askling, J. and T. Bongartz (2008). "Malignancy and biologic therapy in rheumatoid arthritis." Current Opinion in Rheumatology 20(3): 334-339.

Askling, J. and W. Dixon (2008). "The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis." Current Opinion in Rheumatology 20(2): 138-144.

Baecklund, E., Y. Natkunam, et al. (2008). "Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis." British Journal of Haematology 141(1): 69-72.

Bergman, K. O., L. Ask, et al. (2008). "Importance of boreal grasslands in Sweden for butterfly diversity and effects of local and landscape habitat factors." Biodiversity and Conservation 17(1): 139-153.

Bergquist, A., S. M. Montgomery, et al. (2008). "Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis." Clinical Gastroenterology and Hepatology 6(8): 939-943.

Hildebrand, H., P. Malmborg, et al. (2008). "Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease." Scandinavian Journal of Gastroenterology 43(8): 961-966.

Knight, A., A. Ekbom, et al. (2008). "What is the significance in routine care of c-ANCA/PR3-ANCA in the absence of systemic vasculitis? A case series." Clinical and Experimental Rheumatology 26(3): S53-S56.

Knight, A., S. Sandin, et al. (2008). "Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease." Arthritis and Rheumatism 58(1): 302-307.

Smedby, K. E., J. Askling, et al. (2008). "Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update." Journal of Internal Medicine 264(6): 514-527.

2007

Askling, J., C. M. Fored, et al. (2007). "Timedependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists (vol 66, pg 1339, 2007)." Annals of the Rheumatic Diseases 66(11): 1548-1548.

Askling, J., C. M. Fored, et al. (2007). "Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists." Annals of the Rheumatic Diseases 66(10): 1339-1344.

Bresso, F., J. Askling, et al. (2007). "Potential role for the common cystic fibrosis AF508 mutation in Crohn's disease." Inflammatory Bowel Diseases 13(5): 531-536.

Carlens, C., L. Brandt, et al. (2007). "The inflammatory reflex and risk for rheumatoid arthritis: a case-control study of human vagotomy." Annals of the Rheumatic Diseases 66(3): 414-416.

Ortqvist, A., F. Granath, et al. (2007). "Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area." European Respiratory Journal 30(3): 414-422.

2006

Askling, J., C. M. Fored, et al. (2006). "Swedish registers to examine drug safety and clinical issues in RA." Annals of the Rheumatic Diseases 65(6): 707-712.

Askling, J., L. Klareskog, et al. (2006). "Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study." Annals of the Rheumatic Diseases 65(9): 1184-1187.

Baecklund, E., C. Backlin, et al. (2006). "Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis." Arthritis and Rheumatism 54(12): 3774-3781.

Baecklund, E., A. Iliadou, et al. (2006). "Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis." Arthritis and Rheumatism 54(3): 692-701.

Bjornadal, L., L. Brandt, et al. (2006). "Impact of parental history on patients' cardiovascular mortality in rheumatoid arthritis." Annals of the Rheumatic Diseases 65(6): 741-74

Knight, A., A. Ekbom, et al. (2006). "Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001." Journal of Rheumatology 33(10): 2060-2063.

Landgren, O., M. Bjorkholm, et al. (2006). "Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma." International Journal of Cancer 118(2): 449-452.

Ludvigsson, J. F., J. Askling, et al. (2006). "Diagnosis underlying appendectomy and coeliac disease risk." Digestive and Liver Disease 38(11): 823-828.

Sandin, S., H. Hjalgrim, et al. (2006). "Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was." Cancer Epidemiology Biomarkers & Prevention 15(7): 1295-1300.

Smedby, K. E., E. Baecklund, et al. (2006). "Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics." Cancer Epidemiology Biomarkers & Prevention 15(11): 2069-2077.

Smedby, K. E., H. Hjalgrim, et al. (2006). "Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype." Journal of the National Cancer Institute 98(1): 51-60.

2005

Askling, J., L. Brandt, et al. (2005). "Risk of haematopoietic cancer in patients with inflammatory bowel disease." Gut 54(5): 617-622.

Askling, J., C. M. Fored, et al. (2005). "Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists." Annals of the Rheumatic Diseases 64(10): 1414-1420.

Askling, J., C. M. Fored, et al. (2005). "Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden." Arthritis and Rheumatism 52(7): 1986-1992.

Askling, J., C. M. Fored, et al. (2005). "Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists." Annals of the Rheumatic Diseases 64(10): 1421-1426.

Askling, J., L. Klareskog, et al. (2005). "Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis." Annals of the Rheumatic Diseases 64(12): 1765-1768.

Smedby, K. E., M. Akerman, et al. (2005). "Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma." Gut 54(1): 54-59.

van Vollenhoven, R. F. and J. Askling (2005). "Rheumatoid arthritis registries in Sweden." Clinical and Experimental Rheumatology 23(5): S195-S200.

2004

Baecklund, E., J. Askling, et al. (2004). "Rheumatoid arthritis and malignant lymphomas." Current Opinion in Rheumatology 16(3): 254-261.

Bergman, K. O., J. Askling, et al. (2004). "Landscape effects on butterfly assemblages in an agricultural region." Ecography 27(5): 619-628.

Knight, A., J. Askling, et al. (2004). "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide." Annals of the Rheumatic Diseases 63(10): 1307-1311.

Lambe, M., R. Cerrato, et al. (2004). "Maternal breast cancer risk after the death of a child." International Journal of Cancer 110(5): 763-766.

Osby, E., J. Askling, et al. (2004). "Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma." Acta Oncologica 43(3): 297-301.

Pettersson, A., M. Kaijser, et al. (2004). "Women smoking and testicular cancer: One epidemic causing another?" International Journal of Cancer 109(6): 941-944.

2003

Cope, J. U., J. Askling, et al. (2003). "Appendectomy during childhood and adolescence and the subsequent risk of cancer in Sweden." Pediatrics 111(6): 1343-1350.

Ekstrom, K., H. Hjalgrim, et al. (2003). "Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives." Arthritis and Rheumatism 48(4): 963-970.

Elmberg, M., R. Hultcrantz, et al. (2003). "Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives." Gastroenterology 125(6): 1733-1741.

Hildebrand, H., Y. Finkel, et al. (2003). "Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001." Gut 52(10): 1432-1434.

Hjalgrim, H., J. Askling, et al. (2003). "Characteristics of Hodgkin's lymphoma after infectious mononucleosis." New England Journal of Medicine 349(14): 1324-1332.

Jacobsson, L. T. H., M. E. Jacobsson, et al. (2003). "Perinatal characteristics and risk of rheumatoid arthritis." British Medical Journal 326(7398): 1068-1069.

Peters, U., J. Askling, et al. (2003). "Causes of death in patients with celiac disease in a population-based Swedish cohort." Archives of Internal Medicine 163(13): 1566-1572.

Richiardi, L., J. Askling, et al. (2003). "Body size at birth and adulthood and the risk for germ-cell testicular cancer." Cancer Epidemiology Biomarkers & Prevention 12(7): 669-673.

2002

Askling, J., M. Linet, et al. (2002). "Cancer incidence in a population-based cohort of individuals hospitalized with Celiac disease or dermatitis herpetiformis." Gastroenterology 123(5): 1428-1435.

Hjalgrim, H., K. Rostgaard, et al. (2002). "Hematopoietic and lymphatic cancers in relatives of patients with infectious mononucleosis." Journal of the National Cancer Institute 94(9): 678-681.

Knight, A., J. Askling, et al. (2002). "Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis." International Journal of Cancer 100(1): 82-85.

Landgren, O., J. Askling, et al. (2002). "Parental longevity and survival in elderly patients with Hodgkin's lymphoma." Haematologica 87(6): 596-601.

2001

Askling, J., P. W. Dickman, et al. (2001). "Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study." Lancet 357(9252): 262-266.

Askling, J., P. W. Dickman, et al. (2001). "Family history as a risk factor for colorectal cancer in inflammatory bowel disease." Gastroenterology 120(6): 1356-1362.

Askling, J. and A. Ekbom (2001). "Risk of non-Hodgkin's lymphoma following tuberculosis." British Journal of Cancer 84(1): 113-115.

Hjalgrim, H., J. Askling, et al. (2001). "Incidence of Hodgkin's disease in Nordic countries." Lancet 358(9278): 297-298.

2000

Hjalgrim, H., J. Askling, et al. (2000). "Risk of Hodgkin's disease and other cancers after infectious mononucleosis." Journal of the National Cancer Institute 92(18): 1522-1528.

1999

Askling, J., G. Erlandsson, et al. (1999). "Sickness in pregnancy and sex of child." Lancet 354(9195): 2053-2053.

Askling, J., L. Grahnquist, et al. (1999). "Incidence of paediatric Crohn's disease in Stockholm, Sweden." Lancet 354(9185): 1179-1179.

Askling, J., J. Grunewald, et al. (1999). "Increased risk for cancer following sarcoidosis." American Journal of Respiratory and Critical Care Medicine 160(5): 1668-1672.

Askling, J., P. Sorensen, et al. (1999). "Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer?" Annals of Internal Medicine 131(9): 655-+.